2026 Clinical Review on Cancer Rehab

Beyond Survival: Why Cancer Rehabilitation Must Catch Up to Modern Oncology

By Ben Ho Park, MD, PhD, Breast Oncologist

Cancer care has entered a remarkable era of innovation. Today’s therapies are more targeted, more personalized, and in many cases more effective than ever before. Patients are living longer, surviving more complex disease, and benefiting from breakthroughs that would have been unimaginable a generation ago. But with this progress comes a new and urgent reality: many of the newest cancer therapies are leaving behind a different kind of burden—one that doesn’t always end when treatment does.

For decades, the conversation around cancer recovery has focused heavily on surgery, chemotherapy, and radiation. While these remain major contributors to long-term morbidity, the landscape has changed. Modern oncology now includes immunotherapy, targeted therapies, HER2-directed treatments, stem cell and bone marrow transplants, and other precision-based interventions that can profoundly alter a patient’s physiology. These treatments are saving lives—but they are also creating a growing population of survivors living with chronic and sometimes permanent complications.

This is exactly why rehabilitation in cancer care must evolve.

As Dr. Ben Ho Park points out, “with all these great new therapies come also and unfortunately, new chronic side effects.” That statement captures a major blind spot in survivorship medicine. Too often, the success of treatment is measured only by tumor response or remission status, while the patient’s long-term functional decline, organ injury, or inflammatory burden remains underrecognized.

Immunotherapy is a powerful example. These agents have transformed the outlook for many cancers by enabling the immune system to attack malignant cells more effectively. Yet they can also trigger immune-related adverse effects that persist long after treatment is over. Some patients may experience permanent damage to endocrine organs such as the adrenal glands, thyroid, or pancreas—conditions that can fundamentally alter metabolism, energy regulation, and quality of life. What may begin as a treatment response can ultimately become a lifelong endocrine disorder requiring ongoing management and monitoring.

Similarly, bone marrow and stem cell transplant survivors often face one of the most difficult chronic complications in oncology: graft-versus-host disease (GVHD). In its chronic form, GVHD can behave like a systemic autoimmune illness, affecting the skin, lungs, joints, gastrointestinal tract, eyes, and connective tissues. In some patients, it can resemble diseases such as scleroderma in both symptoms and severity. These are not minor residual effects. They can impair mobility, breathing, digestion, resilience, and the basic ability to function comfortably in everyday life.

Other newer therapies bring their own risks. HER2-directed therapies, while highly effective in breast and other HER2-positive cancers, can in some cases contribute to cardiac dysfunction or heart failure. Additional targeted therapies may affect vascular health, nerve function, inflammatory pathways, or organ performance in ways that are not always immediately visible—but are deeply felt by patients over time.

This is where RehabScan enters the conversation with urgency and relevance.

If cancer treatment is becoming more biologically sophisticated, then rehabilitation must become more diagnostically sophisticated as well. Recovery should no longer be defined only by symptom complaints or generalized supportive care. It should include a structured, measurable effort to identify what systems have been altered, what damage may be lingering beneath the surface, and what interventions can help restore function before decline becomes permanent.

Cancer survivorship is no longer just about being alive after treatment. It is about how well a person is able to live, function, think, move, recover, and reclaim quality of life after the therapies that saved them. The next frontier in oncology is not just better treatment—it is better restoration.

And for many survivors, that may be the care that matters most.